Live Breaking News & Updates on Guillaume Renondin

Stay updated with breaking news from Guillaume renondin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pixium Vision receives HealthTech Award for Prima System at the MedTech Forum


Pixium Vision receives HealthTech Award for Prima System at the MedTech Forum
Best Product/Deal for its bionic vision Prima System.
The award, presented at the MedTech Forum 2021, recognizes the most promising game changers developing emerging technologies for healthcare in Europe, and is organized by the NOBEL Projectand hosted by the MedTech Forum.

HealthTech
Lloyd Diamond, Chief Executive Officer of Pixium Vision
.
The Prima System has demonstrated its potential to make a significant improvement to the quality of life of patients with dry AMD and this award recognizes its capacity to improve vision. I would like to thank the entire Pixium Vision team and our collaborators for their dedication in developing the Prima System and progressing it through clinical trials and towards patients in desperate need of ....

France General , Stanford University , United States , United Kingdom , Nordrhein Westfalen , City Of , Comunidad Autonoma De Cataluna , Guillaume Renondin , Entreprise Innovante , Guillaume Van Renterghem , Sophie Baumont , Institute Of Ocular Microsurgery , Medtech Forum , Pixium Vision , Healthtech Award , Prima System , Lloyd Diamond , Chief Executive Officer , Institut De La Vision , Moorfields Eye Hospital , Ocular Microsurgery , பிரான்ஸ் ஜநரல் , ஸ்டான்போர்ட் பல்கலைக்கழகம் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , னோற்ர்ேன் வெஸ்ட்ஃபாலன் ,

Investegate |Pixium Vision Announcements | Pixium Vision: Pixium Vision receives HealthTech Award for Prima System at the MedTech Forum


Lloyd Diamond, Chief Executive Officer of Pixium Vision
.
“The Prima System has demonstrated its potential to make a significant improvement to the quality of life of patients with dry AMD and this award recognizes its capacity to improve vision. I would like to thank the entire Pixium Vision team and our collaborators for their dedication in developing the Prima System and progressing it through clinical trials and towards patients in desperate need of
treatment.”
The Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision in atrophic dry age-related macular degeneration (AMD), is being studied in the pivotal PRIMAvera trial. The study was initiated in Q4 2020 and aims to confirm the safety and the benefits provided by the Prima System and is the last clinical step before seeking market approval in Europe. ....

France General , Stanford University , United States , United Kingdom , Nordrhein Westfalen , City Of , Comunidad Autonoma De Cataluna , Guillaume Renondin , Entreprise Innovante , Guillaume Van Renterghem , Sophie Baumont , Institute Of Ocular Microsurgery , Medtech Forum , Pixium Vision , Healthtech Award , Prima System , Euronext Growth Paris , Lloyd Diamond , Chief Executive Officer , Institut De La Vision , Moorfields Eye Hospital , Ocular Microsurgery , பிரான்ஸ் ஜநரல் , ஸ்டான்போர்ட் பல்கலைக்கழகம் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் ,

Pixium Vision announces its cash position at 31 March 2021 and provides an update on its activities and financial outlook until the end of 2021.


Pixium Vision announces its cash position at 31 March 2021 and provides an update on its activities and financial outlook until the end of 2021.
at
31 March 2021 and provides an update on its activities and financial outlook until the end of 2021.
Paris, 16 April 2021 - 6:00 p.m. CEST - Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces a cash position of €9.7 million at 31 March 2021 and reports on its key developments.
Statement of cash flows summary
In thousands of €
10,566.0
(818.4)
(3,639.4)
(10.8)
2,831.8
9,747.6
4,830.6
Net cash outflow from operating activities in the first three months of 2021 totalled €3.6 million, compared to €2.5 million one year earlier. The increased cash outflow was primarily due to the launch of the PRIMAvera clinical trial i ....

Stanford University , United States , United Kingdom , France General , City Of , Comunidad Autonoma De Cataluna , Guillaume Renondin , Guillaume Van Renterghem , Sophie Baumont , Second Sight Medical Products Inc , Institute Of Ocular Microsurgery , Innovative Company , Paris Commercial Court , Pixium Vision , Euronext Growth Paris , Second Sight Medical Products , Prima System , Age Related Macular Degeneration , Institut De La Vision , Moorfields Eye Hospital , Ocular Microsurgery , ஸ்டான்போர்ட் பல்கலைக்கழகம் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , பிரான்ஸ் ஜநரல் , நகரம் ஆஃப் ,